Table 1.
Comparisons of the baseline characteristics between groups stratified by ACM or CSM
| Variable | Total n=335 |
1-year ACM | 1-year CSM | ||||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| Mortality n=164 |
Survivors n=171 |
P-value | Yes n=141 |
No n=194 |
P-value | ||
| Mean age, years | 45.3±17.7 | 49.5±18.2 | 41.3±16.3 | 0.001 | 47.6±17.5 | 43.7±17.7 | 0.049 |
| Age, years | 0.001 | 0.014 | |||||
| <50 | 204 (60.9) | 82 (50.0) | 122 (71.3) | 75 (53.2) | 129 (66.5) | ||
| ≥50 | 131 (39.1) | 82 (50.0) | 49 (28.6) | 66 (46.8) | 65 (33.5) | ||
| Male, n (%) | 174 (51.9) | 81 (49.4) | 93 (54.4) | 0.360 | 70 (49.6) | 104 (53.6) | 0.474 |
| Race, n (%) | 0.800 | 0.905 | |||||
| White | 259 (77.3) | 129 (78.7) | 130 (76.0) | 109 (77.3) | 150 (77.3) | ||
| Black | 45 (13.4) | 20 (12.2) | 25 (14.6) | 18 (12.8) | 27 (13.9) | ||
| Other | 31 (9.3) | 15 (9.1) | 16 (9.4) | 14 (9.9) | 17 (8.8) | ||
| Year of diagnosis, n (%) | 0.019 | 0.009 | |||||
| <2000 | 70 (20.9) | 43 (26.2) | 27 (15.8) | 39 (27.7) | 31 (16.0) | ||
| ≥2000 | 265 (79.1) | 121 (73.8) | 144 (84.2) | 102 (72.3) | 163 (84.0) | ||
| Classification, n (%) | 0.185 | 0.061 | |||||
| Angiomyosarcoma | 149 (44.5) | 77 (47.0) | 72 (42.1) | 70 (49.7) | 79 (40.7) | ||
| Leiomyosarcoma | 22 (6.6) | 6 (3.7) | 16 (9.4) | 4 (2.8) | 18 (9.3) | ||
| Myxoid sarcoma | 37 (11.0) | 17 (10.4) | 20 (11.7) | 13 (9.2) | 24 (12.4) | ||
| Other types# | 127 (37.9) | 64 (39.0) | 63 (36.8) | 54 (38.3) | 73 (37.7) | ||
| Size of tumor, n (%) | 0.036 | 0.004 | |||||
| ≤5 cm | 63 (18.8) | 28 (17.1) | 35 (20.5) | 21 (14.9) | 42 (21.6) | ||
| >5 cm | 156 (46.6) | 68 (41.5) | 88 (51.5) | 57 (40.4) | 99 (51.0) | ||
| Unknown | 116 (34.6) | 68 (41.5) | 48 (28.1) | 63 (44.7) | 53 (27.3) | ||
| Number of tumor, n (%) | 0.552 | 0.001 | |||||
| 1 | 301 (89.9) | 149 (90.9) | 152 (88.9) | 141 (100) | 160 (82.5) | ||
| ≥2 | 34 (10.1) | 15 (9.1) | 19 (11.1) | 0 (0) | 34 (17.5) | ||
| SEER stage, n (%) | 0.022 | 0.083 | |||||
| Regional | 90 (26.9) | 39 (23.8) | 51 (29.8) | 35 (24.8) | 55 (28.4) | ||
| Localized | 105 (31.3) | 43 (26.2) | 62 (36.3) | 36 (25.5) | 69 (35.6) | ||
| Unstaged/unknown | 13 (3.9) | 9 (5.5) | 4 (2.3) | 6 (4.3) | 7 (3.6) | ||
| Distant | 127 (37.9) | 73 (44.5) | 54 (31.6) | 64 (45.4) | 63 (32.5) | ||
| Radiation therapy, n (%) | 92 (27.5) | 49 (29.9) | 43 (25.1) | 0.332 | 41 (29.1) | 51 (26.3) | 0.572 |
| Chemotherapy, n (%) | 196 (58.5) | 83 (50.6) | 113 (66.1) | 0.004 | 73 (51.8) | 123 (63.4) | 0.033 |
| Surgery, n (%) | 231 (69.0) | 103 (62.8) | 128 (74.9) | 0.017 | 86 (61.0) | 145 (74.7) | 0.007 |
| Regional node surgery, n (%) | 15 (4.5) | 5 (3.0) | 10 (5.8) | 0.292 | 3 (2.1) | 12 (6.2) | 0.063 |
| ACM, n (%) | 164 (49.0) | - | - | - | - | - | - |
| CSM, n (%) | 141 (42.1) | - | - | - | - | - | - |
#
Other types, rhabdomyosarcoma, undifferentiated sarcoma, giant cell sarcoma, synovial sarcoma, osteosarcoma, epithelioid sarcoma, liposarcoma, and histiocytic sarcoma
ACM - 1-year all-cause mortality; CSM - 1-year cancer-specific mortality; SEER - Surveillance, Epidemiology, and End Results